Mirtazapin Biomo (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonising postsynaptic 5‑HT2, 5‑HT3 and histamine H1 receptors. This combined action enhances serotonergic and noradrenergic neurotransmission while producing a calming, sedative effect.

The dosage of Mirtazapin Biomo is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Only a qualified healthcare professional should set the dose and any titration schedule.

Safety data for mirtazapine in pregnancy and lactation are limited. The prescribing physician must weigh potential benefits against possible risks to the fetus or infant and follow local regulatory guidance before use in these populations.

To request Mirtazapin Biomo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mirtazapin Biomo (mirtazapine) belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This profile often results in stronger sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those who need to avoid sedation.

Mirtazapin Biomo should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiry date.

Mirtazapin Biomo is taken orally, usually once daily in the evening to take advantage of its sedative properties. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include the potential for agranulocytosis, severe neutropenia, hepatic dysfunction, and rare cases of Stevens‑Johnson syndrome. Additionally, worsening depression or emergence of suicidal thoughts may occur, especially early in treatment, and require immediate medical attention.

Mirtazapin Biomo is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in those currently receiving monoamine oxidase inhibitors (MAOIs). Caution is also advised for individuals with severe hepatic impairment, uncontrolled hypertension, or a history of seizures.